DIR Return Create A Forum - Home
---------------------------------------------------------
Renewable Revolution
HTML https://renewablerevolution.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: Advances in Health Care
*****************************************************
#Post#: 205--------------------------------------------------
Yes Treating Farm Animals Well is a Human Health Improvement!
By: AGelbert Date: October 29, 2013, 10:27 pm
---------------------------------------------------------
[center]
HTML http://www.youtube.com/watch?v=v0D8uiIIIBw&feature=player_embedded[/center]
This lady decided to change her chicken farming methods despite
industry pressures not to do so over a year ago.
I thanked her and asked her to keep the welfare of the chickens
in mind above and beyond the profit motive while raising them as
this would keep their existence less stressful and their overall
health would improve because, even though we eat them, we should
treat them humanely while they live.
I mentioned she would be much happier as well. Apparently enough
people talked to her this way because she listened!
#Post#: 598--------------------------------------------------
3D Tissue Printing will end the torturing of animals for "S
cience".
By: AGelbert Date: December 22, 2013, 5:02 pm
---------------------------------------------------------
By Marsh Robe
Use of 3D printing for producing human tissue, also called as
bioprinting, has been made commercially viable through the
initiatives of Organovo Holdings (ONVO). Next year, Organovo
will launch its first bioprinted liver tissue. This 3D printing
technology creates human tissue with the help of its own NovoGen
MMX Bioprinter. Organovo aims to provide a technology that will
solve the complex problems of biotech companies by providing an
opportunity to test drugs on functional human tissues to better
understand of drug's effects on the human body. In addition to
this, the company plans to provide therapeutic applications by
providing 3D tissues that can be implanted into the human body
to repair or replace damaged or diseased tissues. The following
is the application of bioprinted human tissue:
[img width=640
height=480]
HTML http://www.otcmagic.com/wp-content/uploads/2012/10/ONVO.jpg[/img]
3D printing is not a new phenomenon, industries use it to build
prototypes and finished products, but use of this technology for
making functional human tissue is a new application. Use of this
technology in biotech will revolutionize drug manufacturing by
providing functional preclinical 3D human tissue, as it
simulates the human biology, thus giving better results during
drug trials. Preclinical trials are usually done on animal
tissues >:(before clinical trials, but animal samples don't
always react the same way as human tissue. [img width=100
height=70]
HTML http://www.nhclc.org/files/nhclc/u38/fl-church-translators-20120622-001.jpg[/img]
Organovo isn't new to drug development; the company worked on
two active research contracts last year with Pfizer and United
Therapeutics Corporation. These collaborative research
agreements involved use of Organovo's NovoGen MMX Bioprinter
technology for facilitating drug discovery, thereby solving the
specific needs of the company.
What is the future of Organovo's technology?
Organovo is working on developing its bioprinting technology for
changing the future of drug trials and therapeutic applications.
Organovo is a development stage company and currently generates
revenue from grants and research agreements like the one with
Pfizer. The company is working on its first product launch next
year. This will be human liver tissue, which will be used in
toxicology by pharma companies.
HTML http://www.pic4ever.com/images/8.gif
Currently, the company doesn't have product based revenue, but
its first product launch next year will be its first commercial
transaction. It will facilitate drug discovery with the tissue's
extended lifespan of up to 40 days. Current liver cells used in
labs have problem replicating the nature of the human liver and
had a short time span of viability. Therefore, this product will
address these issues and will provide human biology simulating
3D printed tissue to companies.
The future of bioprinting is the use of this technology for
making fully functional human organs to meet the customer
demand. The company has demonstrated printing of the first fully
cellular engineered human artery; it uses stem cells from fat
tissue (like bone marrow) to create arteries. Use of Organovo's
cell by cell 3D printing approach in developing human organs for
transplant will be an important milestone, but this technology
is still years away from producing human organs such as the
liver or kidney. These organs require networks of blood vessels
and other tiny structures to live, and 3D printing isn't capable
of integrating blood vessels yet. Therefore, this technology is
limited for regenerative medicine, and it will help in
surgeries.
One cannot expect bioprinting to grow as quickly as traditional
3D printing. The medical world has been using 3D printing
extensively, but use of this technology for bioprinting is a
different ball game.
Up to now, around 5.5 million patients have been treated using
3D parts, from prosthetic limbs to 3D-printed titanium jaw
implants, around the world. 3D printing has been used
extensively for making hearing aids, with more than 10 million
printed hearing aids currently in use around the world. The
medical 3D printing market is expected to grow from $354 million
in 2012 to $965 million in 2019.
In addition, investors cannot expect Organovo to simulate the
growth of 3D printing market leaders 3D Systems (DDD) or
Stratasys (SSYS). 3D Systems specializes in all three 3D
printing segments, i.e prototyping, direct digital
manufacturing, and consumer. It provides end to end solutions in
the 3D printing market, ranging from materials to 3D printers.
On the other hand, Stratasys has focused on industrial grade
printers, but with acquisition of Makerbot, the company now has
a leading position in the consumer segment.
Organovo' changing market sentiments
Market sentiments towards Organovo have been changing quickly.
At the beginning of the year, Organovo's share price was around
$2.36 per share, but in November, the share price was high as
$12.75, thus almost reaching a $1 billion market cap. This was
due to bullish sentiments after the company announced in an
October 22 Conference that it has achieved the 40 days
performance target for its 3D bioprinted liver tissue, which
will be launched in 2014. This October announcement added no new
insight about the company's product pipeline, as it was just a
progress report of previously announced news. Since then, there
have been bearish sentiments towards the stock, and share price
plunged below the $9 mark. Organovo entered an equity
distribution agreement with JMP Securities, in which it may sell
4 million through its sales agent. This will help it raise cash
and strengthen the cash position for funding growth initiatives.
However, it will also put downward pressure on its share price.
So is this the right time to invest in Organovo?
Organovo's future revenue generation remains uncertain. As there
is no new release regarding the company's upcoming product, its
future revenue generation has come into question. The company is
currently dependent on research agreements and grants for
revenue generation, but its first product is expected to launch
by December 2014, thereby creating doubts about Organovo's
revenue next year.
Currently, the share price is benefitting from market sentiments
with no clear fundamental support to the current stock
appreciation. After reaching a market cap close to $1 billion in
November, its share price has fallen, reducing its market cap,
which is currently around $677 million. Its current trailing
twelve months revenue is $693,000, and its price to sales ratio
is just above the 1000 mark. This variation denotes that market
sentiments are driving the stock price without much fundamental
strength.
Bioprinting isn't a fad, and this technology will prosper in the
future. I believe in Organovo' growth potential, so with a
long-term view, investors should invest in this future
technology with the understanding that there might be
volatility. This stock isn't recommended for risk averse
investors.
HTML http://www.desismileys.com/smileys/desismileys_0293.gif
HTML http://seekingalpha.com/article/1911681-how-to-play-organovo-holdings
*****************************************************